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Clinical management of Neisseria gonorrhoeae, a common sexually transmitted bacterial pathogen, is 27 complicated by the ability of the organism to become resistant to antibiotics through genetic mutations and/or 28 acquisition of resistance conferring genes (1) . Antimicrobial resistance in N. gonorrhoeae occurs as 29 chromosomally mediated resistance to a variety of antimicrobial agents, including penicillin, tetracycline, 30 spectinomycin, and fluoroquinolones, and high-level, plasmid-mediated resistance to penicillin and tetracycline 31 (2). The Centers for Disease Control and Prevention (CDC) currently recommends that uncomplicated 32 gonococcal infections be treated with ceftriaxone in combination with azithromycin or doxycycline (3). 33
Combination therapy is hypothesized to lessen survivability of N. gonorrhoeae strain that becomes resistant to 34 one or the other antibiotic. The combination of ceftriaxone or cefixime plus azithromycin was shown to 35 effectively inhibit N. gonorrhoeae growth in vitro through independent actions (4). However, the effect of drug 36 combinations involving azithromycin on N. gonorrhoeae growth has not been well studied. 37
In vitro drug activity against N. gonorrhoeae can be determined by either diffusion or dilution methods. 38
The agar plate dilution method is considered to be the standard reference method and is used in the CDC's 39 The final concentration of azithromycin was 0 to 8.0 g/ml in combination with 0 to 32 g/ml of gentamicin. A 52 similar range of azithromycin dilutions was used in combination with 0 to 64 g/ml of ciprofloxacin and 0 to 8 53 g/ml of rifampicin. Following the addition of antibiotic dilutions, the medium was poured into square 100mm x 54 100mm Petri dishes. The medium was allowed to solidify and the plates were stored at 4 o C for up to one month 55 prior to use. An overnight growth of an isolate on chocolate agar was suspended in Mueller-Hinton broth 56 (Becton Dickinson) to a concentration of 10 8 colony forming units. The bacterial suspensions were inoculated 57 onto the antibiotic containing agar plates using a Steers replicator that allows for up to 36 isolates to be tested 58 on one plate. The minimum inhibitory concentration (MIC; all isolates inhibited), MIC 50 (50% of isolates 59 inhibited) and MIC 90 (90% of isolates inhibited) of single and drug combination was determined after 20 to 24 60 hours incubation at 36.5 o C under 5% CO 2 . For analysis, results were arbitrarily stratified by MIC values into low, 61 medium and elevated groupings to assess differences between these values. There were no medium rifampicin 62 MIC values for isolate grouping. A fractional inhibitory index (FICI) was calculated as previously described (4, 6). 63
The FICI was used to assess synergy (FICI ≤0. There was no antibiotic synergy or antagonism when azithromycin was paired with either gentamicin or 79 ciprofloxacin (Tables 2 and 3 ). Though the overall FICI interpretation of rifampicin and azithromycin was 80 indifference (Table 4) , antagonism was observed with 23 isolates. The azithromycin and rifampicin MIC values 81 for these 23 isolates ranged from 0.125 to 8µg/ml and 0.015 to 8µg/ml, respectively. There was no stratification 82 by single drug MIC values for those isolates in which antagonism was noted between rifampicin and 83 azithromycin. Comparing the genomic sequences of isolates that had drug antagonism to those without may 84 elucidate the mechanisms responsible for these observations. These in vitro data suggest that rifampicin should 85 not be considered in combination with azithromycin for the treatment of gonorrhea. However, there was no 86 reported antagonism when rifampicin was combined with ceftriaxone or cefixime (6). investigating existing antibiotics used in combination may be therapeutically relevant. 
